Filtered By:
Condition: Congestive Heart Failure
Cancer: Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 80 results found since Jan 2013.
McConnell ’ s Bid to Downplay Freezes Undermined by History of Politicians Lying About Their Health
After Senate Minority Leader Mitch McConnell froze during a press conference this month, the Kentucky Republican’s second such episode this summer, his office released a note from the Capitol physician intended to calm those worried about his ability to continue at his job.
Dr. Brian Monahan told McConnell in the letter that there was “no evidence that you have a seizure disorder or that you experienced a stroke, TIA or movement disorder such as Parkinson’s disease.” Monahan suggested the episodes may be related to the Leader’s concussion in March or to dehydration.
[time-brightcove n...
Source: TIME: Health - September 11, 2023 Category: Consumer Health News Authors: Mini Racker Tags: Uncategorized Congress Source Type: news
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Association of urinary nitrate with diabetes complication and disease-specific mortality among adults with hyperglycemia
CONCLUSIONS: Higher urinary nitrate is associated with lower risk of congestive heart failure and diabetic nephropathy, and lower risk of all-cause, CVD, and diabetes mortalities. These findings indicated that inorganic nitrate supplementation can be considered as a supplementary treatment for people with hyperglycemia.PMID:36576885 | DOI:10.1210/clinem/dgac741
Source: The Journal of Clinical Endocrinology and Metabolism - December 28, 2022 Category: Endocrinology Authors: Wenbo Jiang Jia Zhang Ruiming Yang Xinyi Sun Huanyu Wu Jiacheng Zhang Siyao Liu Changhao Sun Lifang Ma Tianshu Han Wei Wei Source Type: research
Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
ConclusionsIn patients who receive clopidogrel after PCI, concomitant use of PPI seems to increase the risk of major cardiovascular events.
Source: Cardiovascular Drugs and Therapy - November 11, 2022 Category: Cardiology Source Type: research
Admission Rates, Time Trends, Risk Factors, and Outcomes of Ischemic and Hemorrhagic Stroke From German Nationwide Data
DISCUSSION: Despite recent advances in acute stroke care over the last decade, the percentage of stroke hospitalizations resulting in death remained unchanged. Further research is needed to determine how best to optimize stroke care pathways for multimorbid patients.PMID:36332988 | DOI:10.1212/WNL.0000000000201259
Source: Cancer Control - November 4, 2022 Category: Cancer & Oncology Authors: Dearbhla M Kelly Jannik Feld Peter M Rothwell Holger Reinecke Jeanette Koeppe Source Type: research
Chronopharmacology of immune-related diseases
Allergol Int. 2022 Jul 15:S1323-8930(22)00075-2. doi: 10.1016/j.alit.2022.06.006. Online ahead of print.ABSTRACTClock genes, circadian pacemaker resides in the paired suprachiasmatic nuclei (SCN), control various circadian rhythms in many biological processes such as physiology and behavior. Clock gene regulates many diseases such as cancer, immunological dysfunction, metabolic syndrome and sleep disorders etc. Chronotherapy is especially relevant, when the risk and/or intensity of the symptoms of disease vary predicably over time as exemplified by allergic rhinitis, arthritis, asthma, myocardial infarction, congestive hea...
Source: Cancer Control - July 19, 2022 Category: Cancer & Oncology Authors: Shigehiro Ohdo Satoru Koyanagi Naoya Matsunaga Source Type: research
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Prevalent Multimorbidity Combinations Among Middle-Aged and Older Adults Seen in Community Health Centers
ConclusionsCHCs are increasingly seeing more complex multimorbidity patterns over time; these most often involve mental health morbidity and advanced cardiometabolic-renal morbidity.
Source: Journal of General Internal Medicine - January 28, 2022 Category: Internal Medicine Source Type: research
Incident cardiovascular disease and long-term exposure to source-specific air pollutants in a Swedish cohort
CONCLUSION: In an area with low to moderate air pollution exposure, we observed significant associations of long-term residential NOx with increased risk of incident CHF and fatal MI, but not with coronary events and stroke.PMID:35074356 | DOI:10.1016/j.envres.2022.112698
Source: Environmental Research - January 25, 2022 Category: Environmental Health Authors: Hanne Krage Carlsen Eva M Andersson Peter Moln ár Anna Oudin Yiyi Xu Janine Wichmann M årten Spanne Emilie Stroh Gunnar Engstr öm Leo Stockfelt Source Type: research
Basis for diurnal exacerbation of neuropathic pain hypersensitivity and its application for drug development
J Biochem. 2021 Dec 30:mvab143. doi: 10.1093/jb/mvab143. Online ahead of print.ABSTRACTIn addition to diurnal rhythms in physiology and behavior, a variety of pathological conditions also exhibit marked day-night changes in symptom intensity, exemplified by allergic rhinitis, arthritis, asthma, myocardial infarction, congestive heart failure, stroke, and chronic pain disorders. Currently, novel therapeutic approaches are facilitated by the development of chemical compounds targeted to key proteins that cause diurnal exacerbation of pathological events. Neuropathic pain is a chronic condition that occurs by tumor-induced ne...
Source: Herpes - December 30, 2021 Category: Infectious Diseases Authors: Satoru Koyanagi Naoki Kusunose Sai Yasukochi Shigehiro Ohdo Source Type: research
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
